From what it looks like it its just another talk about Immunotherapy in relation to GBM
I will say, DI told me explicitly that this discussion is strictly about the Phase III trial. Not about immunotherapy and gbm in general. Specifically about the trial.
So, while it may just be mostly an old data rehash, it's not going to be generalities. It is 100% about DCVax-L. And at least one small tidbit of new info.